vs

Side-by-side financial comparison of Roivant Sciences Ltd. (ROIV) and Upstream Bio, Inc. (UPB). Click either name above to swap in a different company.

Roivant Sciences Ltd. is the larger business by last-quarter revenue ($2.0M vs $668.0K, roughly 3.0× Upstream Bio, Inc.). Upstream Bio, Inc. runs the higher net margin — -6356.1% vs -13301.2%, a 6945.1% gap on every dollar of revenue.

Roivant Sciences Ltd. is an American multinational healthcare company focused on applying technology to drug development and building subsidiary life sciences and health technology companies. It was founded in 2014 by Vivek Ramaswamy and is currently headed by CEO Matt Gline. Roivant maintains its headquarters in New York City as well as major offices in the biotech hubs of Boston and Basel.

TCI Co., Ltd. is a Taiwanese contract development and manufacturing organization (CDMO) specialising in the research, development and production of functional beverages, dietary supplements and skincare products. Headquartered in the Neihu Technology Park in Taipei, TCI evolved from an original trading company founded in 1980 into a CDMO group serving clients across Asia, Europe and North America, and is publicly traded on Taiwan's over-the-counter market under the code 8436.

ROIV vs UPB — Head-to-Head

Bigger by revenue
ROIV
ROIV
3.0× larger
ROIV
$2.0M
$668.0K
UPB
Higher net margin
UPB
UPB
6945.1% more per $
UPB
-6356.1%
-13301.2%
ROIV

Income Statement — Q3 FY2026 vs Q4 FY2025

Metric
ROIV
ROIV
UPB
UPB
Revenue
$2.0M
$668.0K
Net Profit
$-265.9M
$-42.5M
Gross Margin
Operating Margin
-16966.1%
-6911.2%
Net Margin
-13301.2%
-6356.1%
Revenue YoY
-77.8%
Net Profit YoY
-257.0%
EPS (diluted)
$-0.38
$-0.78

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ROIV
ROIV
UPB
UPB
Q4 25
$2.0M
$668.0K
Q3 25
$1.6M
$683.0K
Q2 25
$2.2M
$937.0K
Q1 25
$-39.6M
$566.0K
Q4 24
$9.0M
Q3 24
$4.5M
$607.0K
Q2 24
$8.0M
Q1 24
$28.9M
Net Profit
ROIV
ROIV
UPB
UPB
Q4 25
$-265.9M
$-42.5M
Q3 25
$-113.5M
$-33.7M
Q2 25
$-223.4M
$-40.0M
Q1 25
$-206.5M
$-27.3M
Q4 24
$169.4M
Q3 24
$-230.2M
$-16.0M
Q2 24
$95.3M
Q1 24
$-151.1M
Operating Margin
ROIV
ROIV
UPB
UPB
Q4 25
-16966.1%
-6911.2%
Q3 25
-19492.9%
-5539.4%
Q2 25
-13130.0%
-4732.9%
Q1 25
674.8%
-5656.0%
Q4 24
-3042.6%
Q3 24
-7636.0%
-3112.5%
Q2 24
-1279.5%
Q1 24
-919.5%
Net Margin
ROIV
ROIV
UPB
UPB
Q4 25
-13301.2%
-6356.1%
Q3 25
-7225.9%
-4941.1%
Q2 25
-10292.9%
-4265.3%
Q1 25
521.8%
-4818.0%
Q4 24
1878.3%
Q3 24
-5143.8%
-2634.6%
Q2 24
1192.7%
Q1 24
-522.3%
EPS (diluted)
ROIV
ROIV
UPB
UPB
Q4 25
$-0.38
$-0.78
Q3 25
$-0.17
$-0.63
Q2 25
$-0.33
$-0.74
Q1 25
$-0.28
$-0.51
Q4 24
$0.23
Q3 24
$-0.31
$-6.96
Q2 24
$0.12
Q1 24
$-0.02

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ROIV
ROIV
UPB
UPB
Cash + ST InvestmentsLiquidity on hand
$4.5B
$341.5M
Total DebtLower is stronger
Stockholders' EquityBook value
$4.3B
$339.8M
Total Assets
$5.2B
$353.8M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ROIV
ROIV
UPB
UPB
Q4 25
$4.5B
$341.5M
Q3 25
$4.4B
$372.4M
Q2 25
$4.5B
$393.6M
Q1 25
$4.9B
$431.4M
Q4 24
$5.1B
Q3 24
$5.4B
$220.7M
Q2 24
$5.7B
Q1 24
$6.5B
Total Debt
ROIV
ROIV
UPB
UPB
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
$311.7M
Q1 24
$430.6M
Stockholders' Equity
ROIV
ROIV
UPB
UPB
Q4 25
$4.3B
$339.8M
Q3 25
$4.4B
$378.6M
Q2 25
$4.3B
$408.7M
Q1 25
$4.7B
$445.6M
Q4 24
$5.2B
Q3 24
$5.2B
$-160.3M
Q2 24
$5.4B
Q1 24
$6.0B
Total Assets
ROIV
ROIV
UPB
UPB
Q4 25
$5.2B
$353.8M
Q3 25
$5.1B
$391.2M
Q2 25
$5.0B
$420.5M
Q1 25
$5.4B
$456.2M
Q4 24
$5.8B
Q3 24
$6.2B
$232.7M
Q2 24
$6.5B
Q1 24
$7.2B
Debt / Equity
ROIV
ROIV
UPB
UPB
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
0.06×
Q1 24
0.07×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ROIV
ROIV
UPB
UPB
Operating Cash FlowLast quarter
$-196.5M
$-30.6M
Free Cash FlowOCF − Capex
$-201.4M
FCF MarginFCF / Revenue
-10076.0%
Capex IntensityCapex / Revenue
246.9%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-776.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ROIV
ROIV
UPB
UPB
Q4 25
$-196.5M
$-30.6M
Q3 25
$-185.7M
$-22.2M
Q2 25
$-204.4M
$-39.2M
Q1 25
$-172.6M
$-41.2M
Q4 24
$-207.3M
Q3 24
$-266.8M
Q2 24
$-192.8M
Q1 24
$-108.5M
Free Cash Flow
ROIV
ROIV
UPB
UPB
Q4 25
$-201.4M
Q3 25
$-193.5M
$-22.3M
Q2 25
$-208.4M
Q1 25
$-173.4M
Q4 24
$-209.1M
Q3 24
$-267.8M
Q2 24
$-193.8M
Q1 24
$-108.8M
FCF Margin
ROIV
ROIV
UPB
UPB
Q4 25
-10076.0%
Q3 25
-12317.8%
-3265.6%
Q2 25
-9604.5%
Q1 25
438.1%
Q4 24
-2318.5%
Q3 24
-5984.4%
Q2 24
-2425.5%
Q1 24
-376.1%
Capex Intensity
ROIV
ROIV
UPB
UPB
Q4 25
246.9%
Q3 25
499.6%
9.4%
Q2 25
185.9%
Q1 25
-2.0%
Q4 24
20.3%
Q3 24
22.3%
Q2 24
12.1%
Q1 24
1.2%
Cash Conversion
ROIV
ROIV
UPB
UPB
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
-1.22×
Q3 24
Q2 24
-2.02×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons